Conclusions

In the INBUILD trial in patients with chronic fibrosing ILDs and a progressive phenotype:
- Changes in scores on the L-PF questionnaire suggested that nintedanib may prevent worsening of cough and reduce worsening of dyspnea over 52 weeks
- Change in the PF-IQOLS summary score suggested that nintedanib may reduce worsening of HRQL over 52 weeks.
Further data are needed on the validation of these patient-reported outcomes and on minimum clinically important differences in this patient population.